Antazoline (phosphate)

Antazoline phosphate is an H1 receptor antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect^[1][2][3]. Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC₅₀ of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC₅₀ = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV^[1][2][3]. In Vitro:Antazoline phosphate shows good inhibitory effect on HBV DNA in the supernatant of HepAD38 and Huh7 cells with the value of EC₅₀ is 2.910 μmol/L and 2.349 μmol/L, respectively^[2]. In Vivo:Antazoline phosphate (IP; 0.01 ml/g; 30min) as H1 receptor antagonists diminishes the anticonvulsant activity of carbamazepine and diphenylhydantoin^[3].